CorMedix announced its strategic initiative with Boston Medical Center to enhance patient safety and reduce health disparities in structurally marginalized populations at risk for bloodstream infections while undergoing dialysis. It is estimated that 25 – 33% of chronic hemodialysis patients with catheters will experience Catheter Related Bloodstream Infections and are three times more likely to experience serious complications, including high mortality rates, within the first few months of dialysis due to CRBSIs. CRBSIs disproportionately impact minority and low-income patient populations on dialysis, who may experience a higher rate of central venous catheter use, resulting in higher medical costs, prolonged hospital stays, increased antimicrobial resistance and higher mortality. This real-world data initiative will evaluate the use of a novel antimicrobial catheter lock solution to reduce the incidence of CRBSIs in patients receiving dialysis through a CVC. The goal of this initiative is to increase healthy outcomes for patients disproportionately impacted by CRBSIs. CorMedix and Boston Medical Center will assess the incidence and scope of CRBSIs, care inequities in patients experiencing CRBSIs, total potential costs of treatment, and CRBSI-related readmissions. This assessment will form the baseline from which CorMedix and Boston Medical Center will evaluate the impact that infection prevention can have on reducing the health disparities that structurally marginalized patient populations often face.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRMD:
- Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections
- Cormedix Inc. To Present At The Jefferies Healthcare Conference
- CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
- CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023
- CorMedix Inc. to Participate in Two Upcoming Investor Conferences